<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229876</url>
  </required_header>
  <id_info>
    <org_study_id>SHBYCL002</org_study_id>
    <nct_id>NCT03229876</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Universal CD19-CART</brief_title>
  <acronym>U-CART</acronym>
  <official_title>A Safety and Efficacy Evaluation of Universal CD19-CART in the Treatment of B Cell Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bioray Laboratory Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bioray Laboratory Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Universal CART(U-CART) has a great advantage for its allogeneic T cell resource. After gene
      disruption of TCRα and HLA-1, U-CART will exempt from immunologic rejection by the receptor,
      and won't initiate GVHD. Thus U-CART would act as a &quot;off-the-shelf&quot; product for the treatment
      of tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chimeric antigen receptor T cell (CART) is a kind of gene engineered T cells by transferring
      an artificial antigen binding receptor. This kind of T cells gains the ability to recognize
      antigen expressing tumor cells and initiate killing process in a HLA-independent way. CD19 is
      the specific cellular marker of B lineage acute leukemia (B-ALL), thus CD19-CART will be
      efficient in treating B lineage ALL.Universal CD19-CART is a kind of &quot;off-the-shelf&quot; product
      originated from health donor's PBMC. The investigators have optimized CRISPR/gRNA
      electroporation to achieve a high gene disruption efficiency in T cells for both TCR-α and
      MHC-1. T cells from health donor have a better proliferation ability and anti-tumor efficacy
      than the patients.Besides, enough number of CART cells can be produced from one donor to meet
      the need of dozens of enrolled patients. This kind of universal CD19-CART has been tested in
      animal experiment for its GVHD satefy and anti-tumor efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multi-center, single arm, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety evaluation of CD19-UCART</measure>
    <time_frame>Baseline up to 28 days after T cell infusion</time_frame>
    <description>Dose Limiting Toxicities (DLTs) occurence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-tumor efficacy of CD19-UCART for B-ALL</measure>
    <time_frame>At day 90, and overall</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vivo persistence of CART cells</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>Duration of persistence of CD19-UCART cells after treatmenttomography scan.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>universal CD19-CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a conditioning therapy with cyclophosphamide and fludarabine before CART therapy. CD19-UCART cells will be injected intravenously (IV) on day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>universal CD19-CART</intervention_name>
    <description>Patients will get one course of CART treatment. There are three doses of CD19-UCART: 5-10*10~4/KgBW、2-4*10~5/KgBW、1-2*10~6/KgBW.</description>
    <arm_group_label>universal CD19-CART</arm_group_label>
    <other_name>CD19-UCART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously confirmed diagnosis as CD19+ ALL within 18 months.

          2. ALL in CR2 or CR3 and not eligible for allogeneic SCT or relapse after allogeneic SCT.

          3. Relapsed or treatment refractory B-ALL.

          4. Expected survival &gt;12W.

          5. Creatinine &lt; 2.5 mg/dl.

          6. ALT/AST &lt; 3x normal

          7. Bilirubin &lt;2.0 mg/dl

          8. Have the capacity to give informed consent

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Uncontrolled active infection.

          3. Active hepatitis B or hepatitis C infection.

          4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
             exclusionary.

          5. Previously treatment with any gene therapy products.

          6. Any uncontrolled active medical disorder that would preclude participation as
             outlined.

          7. HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunxiao Xu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Li, phD</last_name>
    <phone>+8602164340008</phone>
    <email>wli@bioraylab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Bioray Laboratory Inc.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei Li, PhD</last_name>
      <phone>+8618621670308</phone>
      <email>adamweili@126.com</email>
    </contact>
    <investigator>
      <last_name>Yunxiao Xu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jumei Shi, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.</citation>
    <PMID>28123068</PMID>
  </reference>
  <reference>
    <citation>Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin Cancer Res. 2017 May 1;23(9):2255-2266. doi: 10.1158/1078-0432.CCR-16-1300. Epub 2016 Nov 4.</citation>
    <PMID>27815355</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

